BIIB DMA
As of date:2/13/2020
BIIB stock price:334.25
BIIB 50 DMA:297.77
BIIB 200 DMA:256.34
BIIB MACD (200-50):-41.43

Also see:
BIIB Market Cap History
BIIB Shares Outstanding History
BIIB YTD Return
BIIB RSI
BIIB MACD
BIIB Technical Analysis

SMAWF Makes Notable Cross Below Critical Moving Average
1 hour, 16 minutes ago


EIGR Makes Notable Cross Below Critical Moving Average
1 hour, 17 minutes ago


PACW Makes Bullish Cross Above Critical Moving Average
1 hour, 22 minutes ago


MLCO Crosses Below Key Moving Average Level
1 hour, 22 minutes ago


FLOW Makes Notable Cross Below Critical Moving Average
1 hour, 22 minutes ago


IBERIABANK (IBKC) Shares Cross Below 200 DMA
1 hour, 25 minutes ago


Notable Two Hundred Day Moving Average Cross - FBNC
1 hour, 25 minutes ago


Unity Bancorp Breaks Below 200-Day Moving Average - Notable for UNTY
1 hour, 26 minutes ago


Westlake Chemical (WLK) Shares Cross Below 200 DMA
1 hour, 46 minutes ago


Banco Santander (Spain) Breaks Below 200-Day Moving Average - Notable for SAN
1 hour, 46 minutes ago


SRLP Crosses Critical Technical Indicator
1 hour, 56 minutes ago


CNX Midstream Partners (CNXM) Shares Enter Oversold Territory
1 hour, 56 minutes ago


Bullish Two Hundred Day Moving Average Cross - SJI
1 hour, 57 minutes ago


Notable Two Hundred Day Moving Average Cross - ASGN
1 hour, 57 minutes ago


Rapid7 Breaks Below 200-Day Moving Average - Notable for RPD
6 hours, 13 minutes ago


More Technical Analysis News

BIIB DMABIIB MACD
Biogen is a biopharmaceutical company focused on discovering, developing and delivering therapies for people living with neurological and neurodegenerative diseases as well as related therapeutic adjacencies. Co.'s main growth areas include multiple sclerosis (MS) and neuroimmunology; Alzheimer's disease and dementia; neuromuscular disorders, including spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis; movement disorders, including Parkinson's disease; and ophthalmology. Co.'s marketed products include TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, VUMERITY and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA and FUMADERM for the treatment of severe plaque psoriasis.

When researching a stock like Biogen, many investors are the most familiar with Fundamental Analysis — looking at a company's balance sheet, earnings, revenues, and what's happening in that company's underlying business. Investors who use Fundamental Analysis to identify good stocks to buy or sell can also benefit from BIIB Technical Analysis to help find a good entry or exit point. Technical Analysis is blind to the fundamentals and looks only at the trading data for BIIB stock — the real life supply and demand for the stock over time — and examines that data in different ways. One of those ways is to calculate a Simpe Moving Average ("SMA") by looking back a certain number of days. One of the most popular "longer look-backs" is the BIIB 200 day moving average ("BIIB 200 DMA"), while one of the most popular "shorter look-backs" is the BIIB 50 day moving average ("BIIB 50 DMA"). A chart showing both of these popular moving averages is shown on this page for Biogen.
10 Most Oversold S&P 500 Stocks
10 Most Overbought S&P 500 Stocks

10 ETFs With Stocks Insiders Are Buying
10 ETFs With Most Upside To Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active S&P Call & Put Options
Quotes delayed 20 minutes
Get Free SEC filing alerts for BIIB:
BIIB SEC Filing Email Alerts ServiceExternal link
Video: Technical Analysis


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Biogen (BIIB) is categorized under the Healthcare sector; to help you further research DMA, below are some other companies in the same sector:

BMY DMA
BSX DMA
CAH DMA
CELG DMA
CNC DMA
COO DMA
DGX DMA
DHR DMA
DVA DMA
EW DMA
More Healthcare companies »

 

BIIB DMA | www.StockDMA.com | Copyright © 2019 - 2020, All Rights Reserved

Nothing in StockDMA.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.